Lupron Depot-Ped 15mg Inj/1 Mth Kit

Manufacturer ABBVIE Active Ingredient Leuprolide Injection (CPP)(loo PROE lide) Pronunciation loo PROE lide
It is used to delay puberty in children who are maturing too early.
đŸˇī¸
Drug Class
Gonadotropin-releasing hormone (GnRH) agonist
đŸ§Ŧ
Pharmacologic Class
Gonadotropin-releasing hormone (GnRH) analog
🤰
Pregnancy Category
Category X
✅
FDA Approved
Apr 1993
âš–ī¸
DEA Schedule
Not Controlled

Overview

â„šī¸

What is this medicine?

Lupron Depot-Ped is a medicine used to treat children who are going through puberty too early, a condition called central precocious puberty (CPP). It works by stopping the body from making the hormones that cause puberty. This helps to slow down or stop the physical changes of puberty, allowing the child to grow more normally and reach their full adult height.
📋

How to Use This Medicine

Taking This Medication

To ensure your child takes this medication correctly, follow the instructions provided by their doctor. Carefully read all the information given to you and adhere to the guidelines. This medication is administered via injection.

Storing and Disposing of This Medication

If you need to store this medication at home, consult with your child's doctor, nurse, or pharmacist to determine the proper storage procedure.

Missing a Dose

If a dose is missed, contact your child's doctor to receive guidance on the next steps to take.
💡

Lifestyle & Tips

  • Administer the injection exactly as prescribed by the doctor, typically once every 4 weeks.
  • Do not miss doses, as this can lead to a return of pubertal signs.
  • Keep all scheduled appointments for monitoring and follow-up.
  • Maintain a healthy diet and exercise routine as advised by the healthcare provider.
  • Report any new or worsening symptoms to the healthcare team promptly.

Dosing & Administration

đŸ‘¨â€âš•ī¸

Adult Dosing

Standard Dose: Not indicated for adult use for this specific formulation (Lupron Depot-Ped). Adult formulations of leuprolide are used for prostate cancer, endometriosis, and uterine fibroids.
đŸ‘ļ

Pediatric Dosing

Neonatal: Not established
Infant: Not established
Child: For Central Precocious Puberty (CPP): Lupron Depot-Ped 15 mg is administered as a single intramuscular injection once every 4 weeks (28 days). The dose is selected based on the patient's weight at the initiation of therapy. For patients weighing â‰Ĩ 38 kg, the recommended dose is 15 mg once every 4 weeks.
Adolescent: For Central Precocious Puberty (CPP): Lupron Depot-Ped 15 mg is administered as a single intramuscular injection once every 4 weeks (28 days). The dose is selected based on the patient's weight at the initiation of therapy. For patients weighing â‰Ĩ 38 kg, the recommended dose is 15 mg once every 4 weeks.
âš•ī¸

Dose Adjustments

Renal Impairment:

Mild: No specific dose adjustment recommended.
Moderate: No specific dose adjustment recommended.
Severe: No specific dose adjustment recommended.
Dialysis: No specific dose adjustment recommended; leuprolide is a peptide and not significantly cleared by dialysis.

Hepatic Impairment:

Mild: No specific dose adjustment recommended.
Moderate: No specific dose adjustment recommended.
Severe: No specific dose adjustment recommended.

Pharmacology

đŸ”Ŧ

Mechanism of Action

Leuprolide is a synthetic nonapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH). It acts as a potent inhibitor of gonadotropin secretion when given continuously. Initially, it causes a transient increase in the levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, leading to a temporary increase in gonadal steroid production (known as a 'flare' effect). However, continuous administration of leuprolide desensitizes and downregulates GnRH receptors in the pituitary, leading to a profound suppression of LH and FSH secretion. This, in turn, reduces gonadal steroidogenesis (estradiol in females, testosterone in males) to prepubertal levels, thereby arresting the progression of central precocious puberty.
📊

Pharmacokinetics

Absorption:

Bioavailability: Nearly 100% (IM/SC for immediate release); sustained release for depot formulation.
Tmax: Approximately 4 hours after a single intramuscular injection of the depot formulation.
FoodEffect: Not applicable for injectable formulation.

Distribution:

Vd: Approximately 27 L (for immediate release).
ProteinBinding: Approximately 43% to 49%.
CnssPenetration: Limited

Elimination:

HalfLife: Approximately 3 hours (for immediate release leuprolide); the depot formulation provides sustained release over 4 weeks.
Clearance: Not precisely quantified for depot, but primarily renal and hepatic for immediate release.
ExcretionRoute: Primarily renal (urine) for metabolites; a small amount excreted in feces.
Unchanged: Less than 5% of the administered dose is excreted unchanged in urine.
âąī¸

Pharmacodynamics

OnsetOfAction: Initial 'flare' effect within days; therapeutic suppression of gonadotropins and sex steroids typically achieved within 2-4 weeks.
PeakEffect: Suppression of LH/FSH and sex steroids to prepubertal levels by 4 weeks.
DurationOfAction: Approximately 4 weeks (for the 1-month depot formulation).

Safety & Warnings

âš ī¸

Side Effects

Urgent Side Effects: Seek Medical Help Right Away

Although rare, some people may experience severe and potentially life-threatening side effects when taking this medication. If your child exhibits any of the following symptoms, contact their doctor or seek medical attention immediately:

Signs of an allergic reaction, such as:
+ Rash
+ Hives
+ Itching
+ Red, swollen, blistered, or peeling skin with or without fever
+ Wheezing
+ Tightness in the chest or throat
+ Trouble breathing, swallowing, or talking
+ Unusual hoarseness
+ Swelling of the mouth, face, lips, tongue, or throat
A fast heartbeat
Fever
Seizures
Swelling or numbness in the arms or legs
Vaginal bleeding that is not normal
Vaginal itching or discharge
Very bad bone pain
Chest pain
A rare but serious condition called pituitary apoplexy, which can occur within 2 weeks of the first dose. Watch for:
+ Sudden headache
+ Vomiting
+ Passing out
+ Mood changes
+ Eye weakness
+ Inability to move eyes
+ Changes in eyesight
Behavior and mood changes, including:
+ Aggression
+ Crying
+ Depression
+ Emotional ups and downs
+ Restlessness
+ Irritability
+ Suicidal thoughts or actions
Raised pressure in the brain, which can cause:
+ Headache
+ Eyesight problems (blurred vision, double vision, or loss of vision)
+ Pain behind the eye
+ Pain when moving the eye
+ Ringing in the ears
+ Dizziness
+ Severe stomach upset
Severe skin reactions, including:
+ Stevens-Johnson syndrome (SJS)
+ Toxic epidermal necrolysis (TEN)
+ Other serious reactions that can affect body organs and be life-threatening. Seek medical help if your child experiences:
- Red, swollen, blistered, or peeling skin
- Red or irritated eyes
- Sores in the mouth, throat, nose, eyes, genitals, or skin
- Fever
- Chills
- Body aches
- Shortness of breath
- Swollen glands

Other Possible Side Effects

Like all medications, this drug can cause side effects. While many people may not experience any side effects or only minor ones, it's essential to monitor your child's condition and contact their doctor if any of the following side effects occur or persist:

Irritation at the injection site
Headache
Hot flashes
Excessive sweating
Pimples (acne)
Weight gain
Constipation
Diarrhea
Stomach pain
Upset stomach
Vomiting
Common cold symptoms
Nose or throat irritation
Cough
Pain in the arms or legs
* Back pain

This is not an exhaustive list of possible side effects. If you have concerns or questions, consult your child's doctor. You can also report side effects to the FDA at 1-800-332-1088 or online at https://www.fda.gov/medwatch.
🚨

Seek Immediate Medical Attention If You Experience:

  • Continued or worsening signs of puberty (e.g., breast growth, menstrual bleeding, testicular enlargement, pubic hair growth)
  • New or severe headaches
  • Vision problems
  • Mood changes or depression
  • Seizures
  • Severe pain, redness, or swelling at the injection site
  • Signs of an allergic reaction (rash, hives, itching, swelling of the face/lips/tongue, difficulty breathing)
  • Numbness or tingling in the arms or legs, or weakness in the legs (rare, but serious neurological events have been reported with GnRH agonists)
📋

Before Using This Medicine

Before Giving This Medication to Your Child: Important Information to Share with Your Doctor

It is essential to inform your doctor about the following:

If your child has any allergies to this medication, any of its components, or other medications, foods, or substances. Please describe the allergy and the symptoms your child experienced.
If your child is pregnant, as this medication should not be administered during pregnancy.

To ensure safe use, tell your doctor and pharmacist about:

All medications your child is taking, including prescription and over-the-counter drugs, natural products, and vitamins.
Any health problems your child has.

It is crucial to verify that it is safe to give this medication alongside your child's other medications and health conditions. Never start, stop, or change the dosage of any medication your child is taking without first consulting with your doctor.
âš ī¸

Precautions & Cautions

It is essential to inform all of your child's healthcare providers, including doctors, nurses, pharmacists, and dentists, that your child is taking this medication. Regular blood tests will be necessary, as directed by the doctor, to monitor your child's condition. Be sure to discuss any concerns or questions with the doctor.

This medication may interfere with certain laboratory tests, so it is crucial to notify all healthcare providers and lab personnel that your child is taking this drug.

During the initial few weeks of treatment, this medication may cause an increase in certain hormone levels, which can lead to the onset or worsening of puberty symptoms, such as vaginal bleeding or spotting. If your child experiences any new symptoms or if these symptoms persist beyond 2 months of treatment, notify the doctor.

In some cases, this medication may affect growth in children and teenagers. To monitor this potential effect, regular growth checks may be necessary. Discuss this with the doctor to determine the best course of action.

For children of childbearing age, a pregnancy test will be required before starting this medication to confirm that they are not pregnant.

This medication may temporarily affect fertility during treatment, which can lead to difficulty conceiving. However, fertility typically returns to normal once the medication is discontinued. If you have concerns about this potential effect, consult with the doctor.

If your child is sexually active, it is essential to use a non-hormone form of birth control, such as condoms, to prevent pregnancy while taking this medication.

If your child becomes pregnant or is already pregnant, this medication may pose a risk to the unborn baby. If your child is pregnant or becomes pregnant while taking this medication, contact the doctor immediately.

If your child is breastfeeding, inform the doctor, as they will need to discuss the potential risks to the baby and determine the best course of action.
🆘

Overdose Information

Overdose Symptoms:

  • Exaggerated pharmacological effects (e.g., initial flare of pubertal signs)
  • Injection site reactions

What to Do:

There is no specific antidote for leuprolide overdose. Treatment should be symptomatic and supportive. Contact a poison control center or emergency medical services immediately. Call 1-800-222-1222 (Poison Control).

Drug Interactions

Monitoring

đŸ”Ŧ

Baseline Monitoring

Diagnosis of Central Precocious Puberty (CPP)

Rationale: Confirm diagnosis based on clinical signs, bone age, and hormonal evaluation (GnRH stimulation test).

Timing: Prior to initiation of therapy.

GnRH stimulation test

Rationale: To confirm central precocious puberty (LH peak > 5 mIU/mL after GnRH stimulation).

Timing: Prior to initiation of therapy.

Sex hormone levels (LH, FSH, Estradiol/Testosterone)

Rationale: To establish baseline levels and confirm pubertal status.

Timing: Prior to initiation of therapy.

Bone age

Rationale: To assess skeletal maturation and monitor progression.

Timing: Prior to initiation of therapy.

Height and weight

Rationale: To establish baseline growth parameters and monitor growth velocity.

Timing: Prior to initiation of therapy.

📊

Routine Monitoring

Clinical signs of puberty (Tanner staging)

Frequency: Every 3-6 months

Target: Regression or stabilization of pubertal signs.

Action Threshold: Progression of pubertal signs may indicate inadequate suppression or need for dose adjustment.

Sex hormone levels (LH, FSH, Estradiol/Testosterone)

Frequency: Every 3-6 months or as clinically indicated

Target: Suppression to prepubertal levels (e.g., LH < 4 mIU/mL, Estradiol < 20 pg/mL, Testosterone < 20 ng/dL).

Action Threshold: Levels above prepubertal range indicate inadequate suppression.

Bone age

Frequency: Every 6-12 months

Target: Slowing of bone age advancement.

Action Threshold: Rapid bone age advancement may indicate inadequate suppression.

Height and weight

Frequency: Every 3-6 months

Target: Normalization of growth velocity for chronological age.

Action Threshold: Accelerated growth velocity may indicate inadequate suppression.

Injection site reaction

Frequency: At each visit

Target: Minimal or no reaction.

Action Threshold: Severe or persistent reaction requires evaluation.

đŸ‘ī¸

Symptom Monitoring

  • Signs of continued pubertal progression (e.g., breast development, testicular enlargement, pubic hair growth, menstrual bleeding)
  • Headache
  • Hot flashes/flushing
  • Mood changes
  • Injection site pain, swelling, or redness
  • Vaginal bleeding or discharge (especially in the first few weeks of treatment due to flare effect)
  • Signs of allergic reaction (rash, itching, difficulty breathing)

Special Patient Groups

🤰

Pregnancy

Contraindicated in pregnancy. Leuprolide can cause fetal harm when administered to a pregnant woman. It is expected to cause abortion or fetal abnormalities based on its pharmacologic action.

Trimester-Specific Risks:

First Trimester: High risk of fetal harm, including abortion or birth defects.
Second Trimester: High risk of fetal harm.
Third Trimester: High risk of fetal harm.
🤱

Lactation

Contraindicated during lactation. It is not known whether leuprolide is excreted in human milk. Due to the potential for serious adverse reactions in a breastfed infant, breastfeeding should be discontinued during treatment.

Infant Risk: High (L5 - Contraindicated)
đŸ‘ļ

Pediatric Use

Lupron Depot-Ped is specifically indicated and dosed for pediatric patients with central precocious puberty. Safety and efficacy have been established in this population. Close monitoring of pubertal progression and hormone levels is crucial.

👴

Geriatric Use

Not indicated for geriatric patients for central precocious puberty. Leuprolide formulations for other indications (e.g., prostate cancer) are used in geriatric populations.

Clinical Information

💎

Clinical Pearls

  • Ensure proper mixing of the lyophilized powder with the diluent immediately prior to intramuscular injection. Do not use if the solution appears clumpy or settled.
  • Administer the injection deep intramuscularly, rotating injection sites to minimize local reactions.
  • A transient 'flare' effect (temporary increase in pubertal signs, including vaginal bleeding in girls) may occur during the first few weeks of treatment. This is expected and usually resolves.
  • Regular monitoring of clinical signs of puberty, bone age, and hormone levels (LH, FSH, sex steroids) is essential to ensure adequate suppression and guide treatment duration.
  • Treatment is typically continued until the appropriate chronological age for the onset of puberty, or until growth plate fusion is complete, as determined by the treating endocrinologist.
  • Educate patients and caregivers about the importance of adherence to the monthly injection schedule to maintain therapeutic suppression.
🔄

Alternative Therapies

  • Other GnRH agonists (e.g., triptorelin, histrelin implant)
  • Observation (for very mild or slowly progressing cases, or when the child is close to the normal age of puberty)
  • Treatment of underlying cause if CPP is secondary to a treatable condition (e.g., tumor)
💰

Cost & Coverage

Average Cost: Highly variable, typically several thousand dollars per 15mg kit
Insurance Coverage: Specialty Tier (requires prior authorization)
📚

General Drug Facts

If your child's symptoms or health issues persist or worsen, it is essential to contact their doctor promptly. To ensure safe use, never share your child's medication with others, and do not administer someone else's medication to your child. Store all medications in a secure location, out of reach of children and pets, to prevent accidental ingestion. Dispose of unused or expired medications properly; do not flush them down the toilet or pour them down the drain unless instructed to do so by a healthcare professional or pharmacist. If you are unsure about the correct disposal method, consult with your pharmacist, as they can provide guidance on available drug take-back programs in your area.

This medication is accompanied by a Medication Guide, which is a comprehensive patient fact sheet. It is crucial to read this guide carefully and review it again whenever the medication is refilled. If you have any questions or concerns about this medication, discuss them with your doctor, pharmacist, or other healthcare provider.

In the event of a suspected overdose, immediately contact your local poison control center or seek emergency medical attention. Be prepared to provide detailed information about the overdose, including the medication taken, the quantity, and the time it occurred, to ensure prompt and effective treatment.